Qisda: Deepening AI Strategy with Profitability as Top Priority

Central News Agency (Taipei, 29th) LCD manufacturer Qisda held its annual general meeting today. Chairman Peter Chen stated that the 2025 global economy is affected by tariffs, geopolitics, exchange rates, and expanded AI investment, leading to a polarized industrial climate. While AI hardware and semiconductor-related industries are growing rapidly, other sectors face significant challenges. Qisda plans to deepen its AI layout by 2026.

Regarding AI strategy, Qisda continued its professional and diverse governance approach in the board election. General Manager Ko Shu-fen was elected as a director, strengthening the board's expertise in AI empowerment and global operations to inject new momentum for the next stage of growth.

Ko stated that the company will continue to focus on four major business blueprints: AI vision and display, AI infrastructure, AI solutions and smart manufacturing, and AI medical and healthcare. The company will integrate its strengths in hardware manufacturing, system integration, and field applications, while actively expanding R&D capabilities for AI servers and key technologies like high-speed switches for AI data centers to help customers improve operational efficiency.

Qisda's "Great Fleet" of affiliated companies continues to deepen its AI layout, strengthening global operations and high-value business development. Qisda passed its 2025 financial report, earnings distribution, and board election today. The 2025 consolidated revenue was NT$207.9 billion, up 3% year-on-year, with an EPS of NT$0.64 and a cash dividend of NT$1 per share.

Chen noted that Qisda continues to promote value transformation. In 2025, medical business revenue exceeded NT$30.3 billion, a 15% increase, and smart solutions expanded their revenue contribution. Looking ahead to 2026, the primary goal is to increase profitability, deepen AI layout, and strengthen global operations and high-value business development.

In the medical sector, Qisda's investment in BenQ Hospital reached a milestone with its 2025 listing on the Hong Kong Main Board. The funds raised will be used for hospital expansion, facility upgrades, potential M&A, and smart hospital system construction. The medical device business focuses on differentiated products such as hemodialysis, ultrasound, and operating room equipment, actively expanding overseas channels in Southeast Asia to strengthen market competitiveness. The pharmaceutical distribution business continues to expand service points to build the most complete healthcare network.